ArticleMolecular biology of the cell2002
Proteasome regulates the delivery of LDL receptor-related protein into the degradation pathway.
Article in Molecular biology of the cell, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Decreased low-density lipoprotein receptor-related protein 1 expression in pro-inflammatory monocytes is associated with subclinical atherosclerosis.Frontiers in cardiovascular medicine · 2022Article
- Familial hypercholesterolemia class II low-density lipoprotein receptor response to statin treatment.Disease models & mechanisms · 2020Article
- Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation.International journal of molecular sciences · 2019Article
- Mutation-specific peripheral and ER quality control of hERG channel cell-surface expression.Scientific reports · 2019Article
- Hemin induces autophagy in a leukemic erythroblast cell line through the LRP1 receptor.Bioscience reports · 2019Article
- Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer's Disease Mouse Model.Frontiers in aging neuroscience · 2018Article
- High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells.Frontiers in pharmacology · 2017Article
- An extended proteome map of the lysosomal membrane reveals novel potential transporters.Molecular & cellular proteomics : MCP · 2013Article
- Convergence of synapses, endosomes, and prions in the biology of neurodegenerative diseases.International journal of cell biology · 2013Review
- Impaired LDL receptor-related protein 1 translocation correlates with improved dyslipidemia and atherosclerosis in apoE-deficient mice.PloS one · 2012Article
- Recruitment of APPL1 to ubiquitin-rich aggresomes in response to proteasomal impairment.Experimental cell research · 2011Article
- A protein interaction network for Ecm29 links the 26 S proteasome to molecular motors and endosomal components.The Journal of biological chemistry · 2010Article
- Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication.Infection and immunity · 2009Article
- Upregulation and maintenance of gap junctional communication in lens cells.Experimental eye research · 2009Article
- Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes.The Journal of biological chemistry · 2008Article
- Post-translational and transcriptional regulation of DMT1 during P19 embryonic carcinoma cell differentiation by retinoic acid.The Biochemical journal · 2006Article
- Sorting nexin 17 facilitates LRP recycling in the early endosome.The EMBO journal · 2005Article
- Cleavages within the prodomain direct intracellular trafficking and degradation of mature bone morphogenetic protein-4.Molecular biology of the cell · 2004Article
- Regulation of nicotinic receptor expression by the ubiquitin-proteasome system.The EMBO journal · 2004Article
- Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator.Molecular biology of the cell · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
The low-density lipoprotein receptor (LDLR)-related protein (LRP) is a multiligand endocytic receptor that has broad cellular and physiological functions. Previous studies have shown that both tyrosine-based and di-leucine motifs within the LRP cytoplasmic tail are responsible for mediating its rapid endocytosis. Little is known, however, about the mechanism by which LRP is targeted for degradation. By examining both endogenous full-length and a minireceptor form of LRP, we found that proteasomal inhibitors, MG132 and lactacystin, prolong the cellular half-life of LRP. The presence of proteasomal inhibitors also significantly increased the level of LRP at the cell surface, suggesting that the delivery of LRP to the degradation pathway was blocked at a compartment from which recycling of the receptor to the cell surface still occurred. Immunoelectron microscopy analyses demonstrated a proteasomal inhibitor-dependent reduction in LRP minireceptor within both limiting membrane and internal vesicles of the multivesicular bodies, which are compartments that lead to receptor degradation. In contrast to the growth hormone receptor, we found that the initial endocytosis of LRP minireceptor does not require a functional ubiquitin-proteasome system. Finally, using truncated cytoplasmic mutants of LRP minireceptors, we found that a region of 19 amino acids within the LRP tail is required for proteasomal regulation. Taken together our results provide strong evidence that the cellular turnover of a cargo receptor, i.e., LRP, is regulated by the proteasomal system, suggesting a broader function of the proteasome in regulating the trafficking of receptors into the degradation pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.